Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PYGB | P11216 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242663 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2853265 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8522586 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969252 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL12689155 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2857459 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15814770 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL9006 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL10013929 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959591 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101883559-B | Edible film | LINTEC CORP. (JP) | 2011-12-28 | — | — | CN | claimed |
| JP-61040783-A | — | — | None | — | — | JP | disclosed |
| CN-101980702-B | Oral preparation | LINTEC CORP | 2013-01-02 | — | — | CN | disclosed |
| CN-101883559-B | Edible film | LINTEC CORP. (JP) | 2011-12-28 | — | — | CN | disclosed |
| CN-101980702-A | Oral preparation | LINTEC CORP | 2011-02-23 | — | — | CN | disclosed |
| CN-101883559-A | Edible film | LINTEC CORP | 2010-11-10 | — | — | CN | disclosed |
| CN-1893832-A | Chewing gum comprising biological degradable polymers and accelerated degradability | GUMLINK AS (DK) | 2007-01-10 | — | — | CN | disclosed |
| US-20050238735-A1 | Orals dosage Noni formulations | LIFESMART NUTRITION | 2005-10-27 | — | — | US | disclosed |
| US-6616938-B2 | Water soluble bulking agent | JOSMAN LABORATORIES, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20020187179-A1 | Non-steroidal anabolic compositions and associated methods | LIFESMART NUTRITION, INC. | 2002-12-12 | — | — | US | disclosed |
| US-20010036445-A1 | Method of making chewing gum containing colloidal bismuth subcitrate | JOSMAN LABORATORIES, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-0956007-A4 | CHEWING GUM CONTAINING COLLOIDAL BISMUTH SUBCITRATE | JOSMAN LAB INC (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6258376-B1 | TREATING HELICOBACTER INFECTIONS AND GASTROINTESTINAL DISORDERS; ANTIULCER AGENTS | JOSMAN LABORATORIES, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-0956007-A1 | CHEWING GUM CONTAINING COLLOIDAL BISMUTH SUBCITRATE | Josman Laboratories, Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5834002-A | WATER INSOLUBLE GUM BASE WITH WATER SOLUBLE BULK PORTION, FLAVORS, COLLOIDAL BISMUTH SALTS OF HYDROXY CARBOXYLIC AICDS, FOR TREATING HELICOBACTER PYLORI INFECTIONS, ANTIULCER AGENTS | JOSMAN LABORATORIES, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998019669-A1 | CHEWING GUM CONTAINING COLLOIDAL BISMUTH SUBCITRATE | JOSMAN LABORATORIES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| JP-S6140783-A | PREPARATION OF EDIBLE VINEGAR | TOMOOKA TAKAHARU | 1986-02-27 | — | — | JP | disclosed |
| US-4013797-A | MICROCOCCUS, LACTOBACILLUS, PEDIOCOCCUC | MICROLIFE TECHNICS, INC. (US) | 1977-03-22 | — | — | US | disclosed |
| US-3984575-A | LACTOBACILLI | MICROLIFE TECHNICS, INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3953609-A | Method for the growth restriction of undesirable digestive system bacteria in animals and the establishment of lactobacillus lactis NRRL B-5628 | MICROLIFE TECHNICS, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187179-A1 | Non-steroidal anabolic compositions and associated methods | GPR119, IGFBP1, IGFBP5 | MEN1 535/4885KMT2A 2844/4885PYGB 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.